It’s been cool to see a top foundation throw open its doors to any and all ideas, as MacArthur has done with its offer of a single $100 million grant. But this drawn out competition has also sent a wrong message.
Ted Turner's $1 billion pledge to U.N. causes in 1997 ushered in a new era of big philanthropy. Twenty years later, we look at what this gift achieved.
The maker of Marlboro cigarettes pledged about $1 billion to a new foundation dedicated to ending smoking worldwide. Why is it so hard to take this move seriously?
The pharmaceutical company, AmerisourceBergen, started its own grantmaking foundation just two years ago. To get a better sense of it's priorities, we connected with the foundation’s president, Gina Clark.
Diarrheal diseases, often caused by poor sanitation, are the second leading cause of death for children under the age of five in poor countries. Which explains why Gates is sticking with its quest for a better toilet.
HIV/AIDS isn't the compelling global cause it once was. But the Gates Foundation has stuck with this challenge for years. Among other things, it's in hot pursuit of cheaper and faster diagnostic tests.
Let's stop buying the excuse that top philanthropists can’t find smart ways to give away more of their wealth—and start pushing them harder to give more and give now.
With the Trump administration working to cut U.S. support for global family planning services, advocates and funders are in crisis mode. Gates is giving much more. Who else is joining in?
As Bloomberg expands his global health funding with a new focus on reducing deaths from non-communicable diseases, his foundation wants to help more cities embrace proven interventions.
In an era of uncertain federal commitments, how can philanthropy refocus its energies on what remains a profound global health crisis? We talk to the leaders of Funders Concerned About AIDS.
There have only been five cases of polio to date this year and the virus has been eliminated in all but three countries. Still, funders are doubling down to finish the job, putting up $1.2 billion.
With his annual giving now over $600 million, Bloomberg hopes to spread his no-nonsense ideas for improving global health–namely, by looking beyond trendy causes to "overlooked killers."
Clubfoot doesn’t get a lot of attention from global health funders. But one major grantmaker is stepping up here in a big way: the Oak Foundation.
Antibiotic-resistant superbugs are killing ever more people in a trend that could have dire consequences. No funder is more worried about this threat than Wellcome Trust.
In another example of Bloomberg Philanthropies zeroing in on mundane but vital global health issues, the foundation is ramping up its work to prevent drowning deaths in poor countries.
Chicagoland couple Jerry and Susan Kolschowsky, who built a fortune in the food industry, support the poor and hungry near home—and in the developing world.
Continuing our spotlight of new grantmaking action on NTDs, we look at which funders are putting up funds to combat the devastating parasitic disease schistosomiasis.
Derek C. Schrier founded Indaba Capital Management, where he's managing partner. But a major component of his philanthropy with wife Cameron involves South Africa, where Schrier worked to end apartheid.
Neglected tropical diseases inflict a devastating human and economic toll on poor countries. The good news? It’s been a busy year in the global fight against NTDs.
Providing continuous access to essential medicines is a global health challenge where innovation is key—especially where the critical cold chain is concerned. Microneedles are one solution.
While uninterrupted refrigeration is key to successful vaccine delivery, that's no easy thing in poor countries where electricity is spotty. Which is why one nonprofit's tech solution has some funders excited.
Since 80 percent of blindness in the world is preventable, you might think plenty of funders would be working this problem. But that's not the case. So who is in this fight?
In parts of Africa, the mortality rate for pediatric cancer patients can be as high as 90 percent. Many of those deaths can be prevented, and this corporate funder is working to make that happen.
Gates recently sounded the alarm about the risks posed by weaponizing dangerous pathogens. He's not the only deep-pocketed funder who's been moving new resources to address biosecurity issues.
Wellcome Trust, the world's second-largest foundation, spends a fortune to find new health breakthroughs. Now, it's making a push to ensure that research translates into actual health gains.
Trump's harsher version of the "global gag rule" may put huge pressures on private global health funders to fill new and gaping funding gaps. Oh, and it's also likely to actually increase abortions.
The latest annual letter by Bill and Melinda Gates leaves key questions unanswered about where Gates giving might go from here. With $185 billion in play, what might the future hold?
Geography often determines a mother and her newborn’s chances of survival. Merck's philanthropic arm is set on changing that. Here's the latest.
Major data projects are looming ever larger in global health philanthropy. What are funders trying to find out? And are these expensive efforts the best use of grant dollars?
Is the rapid urbanization of the world a good thing when it comes to public health, equity, and more? To find out, Wellcome Trust is funding a five-year study in hundreds of cities.